Recruiting
Phase 1

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Sponsor:

Prelude Therapeutics

Code:

NCT05665530

Conditions

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Mantle Cell Lymphoma (MCL)

Richter's Syndrome

T-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PRT2527

Zanubrutinib

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information